Form 4: Assembly Biosciences Director McHutchison Receives Stock Options

Director John G. McHutchison of Assembly Biosciences, Inc. was granted stock options to purchase 2,750 shares of common stock on May 29, 2024.

Summary

• On May 29, 2024, John G. McHutchison, a director of Assembly Biosciences, Inc., received stock options.
• These options allow him to purchase 2,750 shares of the company's common stock at an exercise price of $15.06 per share.
• The options vest on the earlier of May 29, 2025, or the date of the Issuer's 2025 annual meeting of stockholders, assuming continuous service.
• The options expire on May 29, 2034.
• Following this transaction, McHutchison directly owns 2,750 derivative securities.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The grant of options is generally viewed as a positive sign, aligning director interests with shareholders, but it's a routine event.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting of the options is contingent on continuous service, suggesting an expectation of ongoing involvement from the director.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in the biotechnology industry.
• The size of the grant (2,750 shares) and the vesting schedule (one year or until the next annual meeting) appear typical for a director-level grant in a company of Assembly Biosciences' size and stage.
• Comparable companies such as Gilead Sciences, Vertex Pharmaceuticals, and BioMarin Pharmaceutical also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the option grant as a positive sign, aligning the director's interests with the company's long-term success.
• The director is incentivized to contribute to the company's growth and profitability to increase the value of their options.

Key Dates